High Cancer Burden in Elderly Chinese, 2005–2011

Shugang Li 1,†, Xuefei Zhang 1,†, Yizhong Yan 1, Kui Wang 1, Dongsheng Rui 1, Lijuan Pang 2,* and Feng Li 2,*

1 Department of Public Health and Key Laboratory of Xinjiang Endemic and Ethnic Diseases (Ministry of Education), Shihezi University School of Medicine, No.4 Bei Er Road, Shihezi 832002, China; E-Mails: lishugang@ymail.com (S.L.); zhangxuefei211@163.com (X.Z.); erniu19880215@sina.com (Y.Y.); kwang@hotmail.com (K.W.); ruidongsheng@gmail.com (D.R.)

2 Department of Pathology and Key Laboratory of Xinjiang Endemic and Ethnic Diseases (Ministry of Education), Shihezi University School of Medicine, No.4 Bei Er Road, Shihezi 832002, China

† These authors contributed equally to this work.

* Authors to whom correspondence should be addressed; E-Mails: ocean123456@163.com (L.P.); lifeng7855@126.com (F.L.); Tel./Fax: +86-993-205-7153 (L.F. & L.J.P.).

Academic Editors: Paul B. Tchounwou and William Chi-shing Cho

Received: 12 August 2015 / Accepted: 23 September 2015 / Published: 29 September 2015

Abstract: Objective: Cancer risk increases with age, creating a challenge for the Chinese health system. To inform public health policy and research, we evaluated the cancer burden in elderly Chinese. Methods: Based on the published Chinese Cancer Registry Annual Report or related literature and the China Population and Employment Statistics Yearbooks, we estimated the cancer burden of elderly Chinese, who were representative of the Chinese population. We calculated the cancer incidence, cancer-related mortality, potential years of life lost (PYLL), and disability-adjusted life years (DALYs) in 2005–2011 by age, sex, district (rural, urban), and calendar year using national cancer registry, publication, and census data. The relative ratios (RRs) were determined between the elderly (≥60 years) and young (<60 years). Results: Cancer incidence and related mortality in the elderly were 8.47 and 13.96 times, respectively, those in the young. The PYLL and DALY rates of the elderly were 1.63 and 5.00 times, respectively, those in the young. The PYLL and DALY rates for elderly men and rural districts were higher than for elderly women and urban districts. The RRs for
male sex and rural districts were higher than for female sex and urban districts. RRs increased sharply from 2005 to 2011. Conclusions: The cancer burden in elderly Chinese was higher in men and rural districts than in women and urban districts, which creates considerable challenges for the Chinese health care system. Comprehensive measures for cancer prevention and treatment in the elderly are needed.

Keywords: elderly; cancer; burden of disease; potential years of life lost; disability adjusted of life years

1. Introduction

The latest cancer data from the GLOBOCAN website [1] showed that there were 14.1 million new cancer cases, 8.2 million cancer-related deaths, and 32.6 million people living with cancer (within five years of diagnosis) worldwide in 2012. The incidence and mortality were 182.0/100,000 and 102.4/100,000, respectively, while the 5-year prevalence was 625.0/100,000. With the implementation of measures such as early detection and cancer prevention, screening, and treatment, the incidence and mortality of cancer have recently declined [2,3]. However, it is estimated that new cancer cases will increase worldwide from 12.7 million in 2008 to 21.4 million in 2030, based on the incidence, population growth, and aging [4]. The elderly population is still highly affected by cancer, as based on the latest data regarding the worldwide cancer incidence and related mortality in the elderly (>60 years) [5]. Cancer and tumors are also considered to be related with aging, with approximately 64% of the cancer patients globally aged ≥60 years [2]. Because cancer can cause disability and shorten life expectancy, it seriously affects the quality of life of elderly people, which then increases social burden. Therefore, cancer is a threat to the health of the elderly population, and studies of cancer and the evaluation of the cancer burden in the elderly can help to provide empirical evidence for the government to control and prevent cancer.

Indices of disease burden have become increasingly popular for assessing the threat posed by a disease. The Global Burden of Disease study provided a unique comprehensive framework to systematically assess national trends in age-specific, sex-specific, all-cause, and cause-specific mortality [5]. To evaluate the cancer burden, disability-adjusted life years (DALYs) are important for linking the burden of cancer mortality with the degree of illness and disability in patients and long-term survivors.

The population of China surpassed near 1.4 billion people in 2010 [6]. Because of the size of the agricultural population, weak health care system, and unhealthy lifestyles, China has a higher incidence of cancer and greater cancer-related mortality compared with developed countries [7]. Moreover, the population of China is aging [8]; people aged ≥60 years represent 12% of the entire Chinese population, which exceeds the criterion of 10% for an aging society provided by the United Nations. Because the aging population in China is increasing, the incidence and mortality of cancer in the elderly population have also significantly increased [8]. It is reported that elderly Chinese people often spend their older years alone and are often unhappy, without considerable financial resources; therefore, cancer would result in considerable disease burden.

Despite the increasing cancer incidence in the elderly in China, we were unable to locate any reports regarding the cancer burden in this population. In this study, we aimed to evaluate the cancer burden in
elderly Chinese in 2005–2011 by calculating cancer burden indices, including incidence, mortality, potential years of life lost (PYLLs), DALYs, PYLL rate, and DALY rate. Furthermore, to assess the degree of cancer burden, we derived the relative ratios (RRs) of these indices between the elderly and young. The findings can provide guidance to develop policies for cancer prevention and control in China as well as a reference for future tumor research.

2. Methods

2.1. Data Sources

To obtain data regarding cancer in the elderly Chinese population covering the years 2005–2011, including the incidence and mortality by age, sex, and region, the data for 2005–2009 were collected from the published Chinese Cancer Registry Annual Report of 2008–2012 [9–13], and the data for 2010–2011 were collected from published literature [6,14]. For comparisons, elderly was defined as ≥60 years old, and young was considered <60 years old.

The census of the Chinese population was estimated based on the China Population and Employment Statistics Yearbook of 2006–2012 [6,14–20]. The following formulas were used to estimate the age-specific, sex-specific, and region-specific populations:

\[
\text{Total population} = \frac{\text{sample population}}{\text{sampling rate}} \quad (1)
\]

\[
\text{Urban (rural) population} = \text{total population} \times \text{percentage of urban (rural) population} \quad (2)
\]

\[
\text{Male (female) population} = \text{total population} \times \text{percentage of male (female) population} \quad (3)
\]

\[
\text{Age-specific population} = \frac{\text{every age-specific sample population}}{\text{sampling rate}} \quad (4)
\]

Based on these estimations, 13.71% of the population was ≥60 years old (Figure 1).

![Figure 1. Average distribution of the age-specific population, by sex, in China, 2005–2011.](image)
2.2. Calculation of Indices

Potential Years of Life Lost

In the formula for PYLL Equation (5), $X$ is the median of each age group, $dx$ represents the number of deaths in each age group, and $L$ is the life expectancy based on the China Health Statistics Annuals for the years 2005 and 2010: 2005–2007, 73 years for the entire population, 71 years for men, and 74 years for women; 2008–2011, 74.8 years for the entire population, 72.4 years for men, and 77.4 years for women:

$$PYLL = \sum_{N=1}^{I} dx(L - X)$$  (5)

Because the life expectancy was only reported for 2005 and 2010 in the China Health Statistics Annuals, we calculated the PYLLs for 2005–2007 and 2008–2011 using the life expectancies for 2005 and 2010, respectively.

2.3. Potential Years of life Lost Rate

In the formula for PYLL rate Equation (6), $N$ is the total number of early deaths, defined as death at an age between the upper and lower limits of the age group, and $PYLL$ is the result of Equation (5):

$$PYLL \text{ rate} = \frac{PYLL}{N} \times 1000 \%$$  (6)

2.4. Disability-Adjusted Life Years

In the formula for DALYs Equation (7), $YLL$ is the years of life lost, and $YLD$ represents the years lived with disability:

$$DALY = YLL + YLD$$  (7)

$YLL$ and $YLD$ were calculated using the following Equations (8) and (9):

$$YLL = N \cdot DW \cdot C \cdot e^{(\gamma \alpha) / (\beta + \gamma)} \left\{ e^{-(\beta + \gamma)(L + \alpha)} \left[ (-\beta + \gamma)(L + \alpha - 1) - e^{-(\beta + \gamma) \alpha} \right] \right\}$$  (8)

$$YLD = I \cdot DW \cdot C \cdot e^{(\gamma \alpha) / (\beta + \gamma)} \left\{ e^{-(\beta + \gamma)(L + \alpha)} \left[ (-\beta + \gamma)(L + \alpha - 1) - e^{-(\beta + \gamma) \alpha} \right] \right\}$$  (9)

In the formula for YLL, $N$ is the number of age-specific and sex-specific deaths, while in the formula for YLD, $I$ is the number of new cases. DW represents the weight (DW = 1 when the death occurred). The discount rate ($\gamma$) is typically chosen as 0.03 [21]. $C$ is 0.1658, which is an age weight-adjusted parameter. $\beta$ is a parameter of the age weight function, for which we often include 0.04 [21]. $\alpha$ is the average number of people who are dead or disabled. $L$ is the standardized life expectancy, and we used 80 and 82.5 for men and women [22], respectively.

2.5. Disability Weight

We used the DW values from global disease burden research published by the World Health Organization (WHO) in 2004 [23].
2.6. Disability-Adjusted Life Year Rate

In the formula for DALY rate Equation (10), \( N \) is the number of the population aged between the upper and lower limits of the age group, and DALY is the result of Equation (7):

\[
DALY \text{ rate} = \frac{DALY}{N} \times 1000\text{%} \tag{10}
\]

2.7. Relative Ratio of the Cancer Burden between the Elderly and Young Subjects

The RRs were calculated Equation (11) for the incidence, mortality, PYLL rate, and DALY rate between the elderly and young populations to evaluate the degree of the cancer burden present in the elderly:

\[
\text{Relative Ratio (RR)} = \frac{\text{Incidence (Mortality/PYLL rate/DALY rate) of Elderly Population (≥60)}}{\text{Incidence (Mortality/PYLL rate/DALY rate) of Young Population (<60)}} \tag{11}
\]

2.8. Statistical Analysis

We used DISMOD2 software, which is recommended by the WHO [24], to determine the average course of disease and time of onset for each age group. YLD, YLL, and DALY were calculated using the operating modules provided by the World Bank. SPSS 20.0 (SPSS Inc., Chicago, IL, USA) was used to compare the RRs for incidence, mortality, PYLL rate, and DALY rate between the sexes and districts using \( t \) tests or Wilcoxon tests. \( p < 0.05 \) was considered statistically significant.

2.9. Role of the Funding Source

The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all of the data in the study and had final responsibility for the decision to submit for publication.

2.10. Ethics Statement

This study was approved by the Institutional Ethics Review Board at the First Affiliated Hospital, Shihezi University School of Medicine (2015-076-01). All of the patients’ information was anonymized and de-identified prior to analysis.

3. Results

3.1. Cancer Incidence in the Elderly Population

The cancer incidence in the elderly population in China in 2005–2011 was 1076.24/100,000, which was 8.47 times that of the young population (127.11/100,000). The cancer incidence of the elderly in rural districts (1127.06/100,000) was higher than that in urban districts (1046.46/100,000). The cancer incidence in the elderly men (1390.32/100,000) was higher than that of the elderly women (773.88/100,000).

The RRs of the cancer incidences between the elderly and young were 11.06, 6.00, 8.62, and 8.78 for men, women, urban districts, and rural districts, respectively. The incidence rate of men (≥60) was
statistically higher than that of women and the incidence of rural district (≥60) was higher than that of urban district, respectively (both, \( p < 0.05 \); Table 1). The RRs for men, women, urban districts, and rural districts increased from 2005 to 2011.

| Year | Age Group | All Districts | Urban Districts | Rural Districts |
|------|-----------|---------------|-----------------|-----------------|
|      |           | Male | Female | Total | Male | Female | Total | Male | Female | Total |
| 2005 | ≥60       | 1310.93 | 789.78 | 1149.32 | 1247.38 | 792.42 | 1049.80 | 1523.81 | 744.67 | 1122.05 |
|      | <60       | 113.88 | 118.54 | 116.22 | 104.80 | 124.45 | 114.47 | 145.44 | 101.62 | 123.87 |
|      | RR        | 11.51 | 6.66 | 8.97 | 11.90 | 6.37 | 8.85 | 10.48 | 7.33 | 9.06 |
| 2006 | ≥60       | 1444.62 | 790.05 | 1034.47 | 1295.83 | 792.95 | 1040.31 | 1552.05 | 787.71 | 1163.68 |
|      | <60       | 121.78 | 129.87 | 125.75 | 52.11 | 129.87 | 139.38 | 128.44 | 100.05 | 140.14 |
|      | RR        | 11.04 | 6.10 | 8.46 | 13.49 | 6.94 | 9.67 | 17.30 | 12.14 | 15.05 |
| 2007 | ≥60       | 1316.00 | 791.96 | 1044.04 | 1323.40 | 837.49 | 1076.49 | 1535.06 | 783.63 | 1153.38 |
|      | <60       | 126.77 | 134.45 | 130.54 | 117.91 | 139.38 | 128.44 | 160.05 | 120.00 | 140.41 |
|      | RR        | 10.38 | 5.89 | 8.04 | 11.22 | 5.94 | 8.16 | 17.30 | 12.14 | 15.05 |
| 2008 | ≥60       | 1270.64 | 824.08 | 1046.66 | 1295.83 | 837.49 | 1040.31 | 1552.05 | 787.71 | 1163.68 |
|      | <60       | 130.71 | 141.72 | 136.05 | 117.91 | 139.38 | 128.44 | 155.63 | 118.41 | 137.40 |
|      | RR        | 10.40 | 5.81 | 7.99 | 11.22 | 5.94 | 8.16 | 9.51 | 6.73 | 8.25 |
| 2009 | ≥60       | 1326.41 | 804.97 | 1021.48 | 1566.30 | 971.95 | 1076.66 | 1311.66 | 739.83 | 1022.45 |
|      | <60       | 132.37 | 139.89 | 136.58 | 130.47 | 149.69 | 139.88 | 137.55 | 118.61 | 128.27 |
|      | RR        | 10.02 | 5.75 | 7.18 | 12.01 | 6.49 | 7.70 | 9.54 | 6.24 | 7.97 |
| 2010 | ≥60       | 1297.55 | 727.21 | 1000.44 | 1523.32 | 893.49 | 1034.53 | 962.74 | 1302.32 | 1135.89 |
|      | <60       | 117.42 | 114.41 | 115.96 | 111.50 | 120.19 | 115.71 | 115.06 | 126.96 | 120.83 |
|      | RR        | 11.05 | 6.36 | 8.68 | 13.66 | 7.43 | 10.89 | 8.37 | 10.26 | 9.40 |
| 2011 | ≥60       | 1760.32 | 688.54 | 1211.78 | 1291.49 | 978.97 | 1131.61 | 1283.72 | 890.98 | 1082.80 |
|      | <60       | 136.16 | 124.43 | 130.49 | 112.54 | 98.54 | 105.77 | 120.84 | 83.27 | 102.67 |
|      | RR        | 12.93 | 5.53 | 9.29 | 11.48 | 9.93 | 10.70 | 10.62 | 10.70 | 10.55 |
| Total | <60       | 125.67 | 129.03 | 127.11 | 115.38 | 128.24 | 121.47 | 143.21 | 113.38 | 128.42 |
|      | RR        | 11.06 | 6.00 | 8.47 | 11.10 | 6.60 | 8.82 | 9.77 | 7.62 | 8.78 |

Notes: * Comparison of the incidence rate between men and women, Wilcoxon \( W = 28.0, p = 0.002; \) 
# represents the comparison of incidence rate between rural and urban districts, Wilcoxon \( W = 35.0, p = 0.025. \)

The top ten cancer types in the elderly men were lung, stomach, colon, rectum and anus, esophagus, liver, kidney, prostate, pancreas, lymphoma, and thyroid gland cancers, while those in the elderly women were lung, colon, rectum and anus, stomach, breast, esophageal, liver, ovarian, uterine, thyroid gland, and cervical cancers (Figure 2).

![Figure 2](image-url)
### Table 2. Changes in the ranking of the top ten cancer incidences in China, 2005–2011.

| Rank | 2005         | ICD10 | Incidence | 2006         | ICD10 | Incidence | 2007         | ICD10 | Incidence | 2008         | ICD10 | Incidence | 2009         | ICD10 | Incidence | 2010         | ICD10 | Incidence | 2011         | ICD10 | Incidence |
|------|--------------|-------|-----------|--------------|-------|-----------|--------------|-------|-----------|--------------|-------|-----------|--------------|-------|-----------|--------------|-------|-----------|--------------|-------|-----------|
| 1    | C33–34       | 47.34 | C33–34    | 49.7         | C33–34| 51.25     | C33–34       | 54.75 | C33–34    | 53.57        | C33–34| 46.08     | C33–34       | 48.32 |
| 2    | C16          | 32.23 | C16       | 35.02        | C16   | 33.68     | C16          | 37.88 | C16       | 36.21        | C50   | 32.43     | C50          | 37.86 |
| 3    | C22          | 26.89 | C18–21    | 29.07        | C18–21| 29.62     | C18–21       | 31.39 | C18–21    | 29.44        | C16   | 30.77     | C16          | 31.21 |
| 4    | C18–21       | 26.89 | C22       | 26.6         | C22   | 27.11     | C22          | 28.17 | C22       | 28.71        | C22   | 27.29     | C22          | 26.39 |
| 5    | C50          | 20.13 | C50       | 21.05        | C50   | 21.59     | C50          | 23.82 | C15       | 22.14        | C15   | 21.88     | C18–21       | 23.03 |
| 6    | C15          | 19.55 | C15       | 18.79        | C15   | 19.86     | C15          | 20.85 | C50       | 21.21        | C18–21| 20.90     | C15          | 21.62 |
| 7    | C25          | 6.59  | C25       | 7.45         | C25   | 7.28      | C25          | 8.55  | C25       | 7.28         | C53   | 11.98     | C53          | 13.4  |
| 8    | C67          | 6.41  | C67       | 6.85         | C67   | 6.98      | C67          | 7.49  | C81–85, 88, 90, 96 | 6.68 | C54–55 | 7.44 | C54–55 | 8.79 |
| 9    | C81–85, 88, 90, 96 | 6.16 | C81–85, 88, 90, 96 | 6.43 | C70–72 | 6.79 | C81–85, 88, 90, 96 | 7.21 | C67 | 6.61 | C56 | 6.47 | C61 | 7.1 |
| 10   | C70–72       | 5.91  | C70–72    | 6.39         | C81–85, 88, 90, 96 | 6.06 | C70–72 | 7.03 | C73 | 6.56 | C70–72 | 6.00 | C56 | 6.89 |

Note: C33–C34 represents Trachea, Bronchus &Lung; C16 represents Stomach; C22 represents Liver; C18–21 represents Colon, Rectum &Auns; C50 represents Breast; C15 represents esophagus; C25 represents Pancreas; C67 represents Bladder; C81–85, 88, 90, 96 represents Lymphoma; C70–72 represents Brain & Central Nervous System; C73 represents Thyroid; C54–55 represents Uterus &Unspecified; C56 represents Ovary; C53 represents Cervix; C61 represents Prostate.
The rankings of the cancer incidences in the elderly remained consistent from 2005 to 2011. Lung cancer was the top-ranked cancer, while breast cancer displaced stomach cancer in the second rank. The cancers specific to women became increasingly common and moved to the list of the top ten cancer incidences. In particular, breast cancer increased from the fifth position in 2005 to the second position in 2010. In addition, ovarian and cervical cancers moved to the top ten cancer list in 2010 (Table 2).

3.2. Cancer-Related Mortality in the Elderly Population

Cancer-related mortality in the elderly population in China in 2005–2011 was 807.38/100,000, which was 13.96 times that of the young population (57.82/100,000). In addition, mortality in the elderly in rural districts was 901.21/100,000 higher than that in urban districts (794.42/100,000). Mortality in elderly men was 1071.48/100,000, which was higher than that of elderly women (553.15/100,000).

The RR of mortality between the elderly and young were 14.72, 13.06, 15.08, and 12.14 for men, women, urban districts, and rural districts, respectively. The mortality for men and rural districts of the elderly were significantly higher than for women and urban districts (all, \( p < 0.05 \); Table 3). The RR in all districts were higher in 2011 than in the other years and significantly increased from 2005 to 2011.

### Table 3. Cancer-related mortality in the elderly (≥60 years) and young (<60 years) populations in China, 2005–2011.

| Year | Age Group | All Districts | Urban District | Rural District |
|------|-----------|---------------|----------------|---------------|
|      |           | Male | Female | Total | Male | Female | Total | Male | Female | Total |
| 2005 | ≥60       | 1054.66 | 591.13 | 815.64 | 949.53 | 572.18 | 754.95 | 1307.74 | 655.04 | 971.18 |
|      | <60       | 67.88  | 40.97  | 54.64  | 56.50  | 36.86  | 46.83  | 105.72 | 54.59  | 80.56  |
|      | RR        | 15.54  | 14.43  | 14.93  | 16.81  | 15.52  | 16.12  | 12.37  | 12.00  | 12.06  |
| 2006 | ≥60       | 1042.03 | 575.40 | 804.93 | 980.75 | 558.20 | 766.05 | 1310.35 | 651.28 | 975.47 |
|      | <60       | 71.64  | 42.60  | 57.38  | 28.33  | 16.91  | 22.62  | 64.89  | 33.61  | 49.25  |
|      | RR        | 14.55  | 13.51  | 14.03  | 13.42  | 33.01  | 33.87  | 20.19  | 19.38  | 19.81  |
| 2007 | ≥60       | 1025.83 | 573.51 | 796.08 | 996.27 | 580.16 | 743.73 | 1322.58 | 658.20 | 985.11 |
|      | <60       | 74.60  | 42.77  | 58.98  | 64.99  | 39.18  | 52.33  | 109.05 | 55.92  | 82.98  |
|      | RR        | 13.75  | 13.41  | 13.50  | 14.81  | 14.21  | 12.13  | 11.77  | 11.87  |        |
| 2008 | ≥60       | 1016.81 | 565.05 | 787.32 | 1064.44 | 608.57 | 751.71 | 1247.22 | 630.46 | 933.91 |
|      | <60       | 73.58  | 44.07  | 59.13  | 67.06  | 41.18  | 54.39  | 101.38 | 56.75  | 79.52  |
|      | RR        | 13.82  | 12.82  | 13.32  | 15.87  | 14.78  | 13.82  | 12.30  | 11.11  | 11.74  |
| 2009 | ≥60       | 1016.70 | 566.45 | 788.98 | 1149.20 | 659.30 | 766.66 | 1104.36 | 469.52 | 783.29 |
|      | <60       | 75.22  | 44.45  | 60.15  | 69.48  | 41.63  | 55.84  | 88.34  | 51.25  | 70.18  |
|      | RR        | 13.52  | 12.74  | 13.12  | 16.54  | 15.33  | 13.73  | 12.50  | 9.16   | 11.16  |
| 2010 | ≥60       | 989.67  | 529.83 | 755.20 | 1120.87 | 628.02 | 748.37 | 1020.56 | 516.96 | 763.78 |
|      | <60       | 68.31  | 41.00  | 55.07  | 60.61  | 37.95  | 49.63  | 76.35  | 44.23  | 60.78  |
|      | RR        | 14.49  | 12.92  | 13.71  | 18.49  | 16.55  | 15.08  | 13.37  | 11.69  | 12.57  |
| 2011 | ≥60       | 1345.95 | 474.91 | 900.34 | 949.53 | 572.18 | 754.95 | 951.18 | 602.72 | 772.92 |
|      | <60       | 78.09  | 40.56  | 59.94  | 56.50  | 36.86  | 46.83  | 61.17  | 25.19  | 36.37  |
|      | RR        | 17.24  | 11.71  | 15.02  | 16.81  | 15.52  | 16.12  | 15.55  | 13.93  | 17.66  |
| Total| ≥60       | 1071.48 * | 553.15 * | 807.38 | 950.02 | 556.30 | 749.42 * | 1206.81 | 607.02 | 901.21 * |
|      | <60       | 72.80  | 42.34  | 57.82  | 62.43  | 36.53  | 49.69  | 96.65  | 51.02  | 74.23  |
|      | RR        | 14.72  | 13.06  | 13.96  | 15.22  | 15.23  | 15.08  | 12.49  | 11.90  | 12.14  |

Notes: * depicts that the comparison of mortality between male and female, Wilcoxon \( W = 28.0, p = 0.002 \); * represents that the comparison of mortality of rural and urban district, Wilcoxon \( W = 30.0, p = 0.004 \).
Table 4. Changes in the ranking of the top ten cancers for mortality in China, 2005–2011.

| Rank | 2005 ICD10 Mortality | 2006 ICD10 Mortality | 2007 ICD10 Mortality | 2008 ICD10 Mortality | 2009 ICD10 Mortality | 2010 ICD10 Mortality | 2011 ICD10 Mortality |
|------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| 1    | C33–C34 42.59         | C33–C34 44.15         | C33–C34 45.5          | C33–C34 46.07         | C33–C34 45.57         | C33–C34 37           | C33–C34 39.27         |
| 2    | C22 25.04             | C16 26.08             | C22 25.91             | C16 26.58             | C22 26.04             | C22 23.76             | C22 23.93             |
| 3    | C16 23.9              | C22 25.83             | C16 24.59             | C22 25.84             | C16 25.88             | C16 21.89             | C16 22.08             |
| 4    | C15 15.78             | C15 15.26             | C15 15.8              | C15 16.24             | C15 16.77             | C15 15.85             | C15 16.25             |
| 5    | C18–21 12.83          | C18–21 13.39          | C18–21 14.15          | C18–21 14.82          | C18–21 14.23          | C18–21 10.05          | C18–21 11.11          |
| 6    | C25 6.09              | C25 7.02              | C25 7.15              | C25 7.56              | C25 6.61              | C50 8.65              | C50 9.21              |
| 7    | C50 4.85              | C50 4.59              | C50 4.67              | C50 5.23              | C50 5.13              | C25 4.39              | C25 5.4               |
| 8    | C91–95 3.77           | C91–95 4.09           | C91–95 4.04           | C91–95 3.99           | C91–95 4.28           | C70–72 3.55           | C70–72 3.77           |
| 9    | C70–72 3.46           | C70–72 4.08           | C70–72 3.95           | C70–72 3.99           | C70–72 3.87           | C91–95 3.47           | C53 3.56              |
| 10   | C81–85, 88, 90, 96 3.4 | C81–85, 88, 90, 96 3.63 | C81–85, 88, 90, 96 3.64 | C81–85, 88, 90, 96 3.96 | C81–85, 88, 90, 96 3.75 | C53 3.37              | C91–95 3.53           |

Notes: C33–C34 represent Trachea, Bronchus & Lung; C16 represent Stomach; C22 represent Liver; C18–21 represent Colon, Rectum & Anus; C50 represent Breast; C15 represent esophagus; C25 represent Pancreas; C81–85, 88, 90, 96 represent Lymphoma; C70–72 represent Brain & Central Nervous System; C91–95 represent Leukemia.
The ranking of cancer-related mortality in elderly Chinese was consistent from 2005 to 2011. The top three cancers for mortality were lung, liver, and stomach cancers. Since 2010, breast cancer-related mortality has considerably increased, moving from the seventh position to the sixth position. In 2011, cervical cancer-related mortality was in the ninth position (Figure 3, Table 4).

3.3. Potential Years of Life Lost in the Elderly Population

The PYLL in the elderly (26,901,836 person years) was lower than that of the young because the population base of the elderly was less than that of the young (Table 5). The PYLL rate was 21.08/1000, which was 1.63 times that of the young (12.90/1000). The PYLL of the elderly in urban districts was 10,930,841 person years, and the PYLL rate was 18.19/1000, which was 1.63 times that of the young (11.19/1000).

| Year | Age Group | All Districts | | | | Urban District | | | | Rural District | | |
|------|-----------|---------------|-----------------|-----------------|-------------|-----------------|-------------|-----------------|-------------|-----------------|-------------|-----------------|-------------|
|      |           | Male          | Female          | Total           | Male          | Female          | Total           | Male          | Female          | Total           | Male          | Female          | Total           |
| 2005 | ≥60       | 1,940,975     | 1,435,404       | 3,376,379       | 712,643       | 554,254         | 1,266,896       | 1,585,342     | 1,083,912       | 2,669,253       | 8,576,569     | 5,898,270       | 14,474,840     |
|      | <60       | 8,576,569     | 5,898,270       | 14,474,840      | 3,114,428     | 2,315,123       | 5,429,551       | 7,399,534     | 4,342,268       | 11,741,801      | 64,671,541    | 39,195,223      | 103,866,764    |
| 2006 | ≥60       | 1,710,157     | 1,176,729       | 2,886,887       | 662,942       | 464,683         | 1,127,625       | 1,399,645     | 938,557         | 2,338,202       | 8,545,603     | 5,639,417       | 14,185,020     |
|      | <60       | 8,545,603     | 5,639,417       | 14,185,020      | 3,288,525     | 2,265,025       | 5,553,550       | 7,284,433     | 4,294,740       | 11,579,174      | 78,901,914    | 55,354,055      | 134,256,078    |
| 2007 | ≥60       | 1,760,106     | 1,178,332       | 2,938,438       | 673,990       | 469,998         | 1,143,988       | 1,415,688     | 896,830         | 2,312,518       | 8,846,914     | 5,568,689       | 14,415,603     |
|      | <60       | 8,846,914     | 5,568,689       | 14,415,603      | 3,494,023     | 2,323,737       | 5,817,760       | 6,976,145     | 3,864,941       | 10,841,085      | 64,671,541    | 39,195,223      | 103,866,764    |
| 2008 | ≥60       | 1,804,156     | 1,213,281       | 3,017,437       | 730,199       | 509,699         | 1,239,898       | 1,409,673     | 873,989         | 2,283,662       | 8,650,169     | 5,764,012       | 14,414,180     |
|      | <60       | 8,650,169     | 5,764,012       | 14,414,180      | 3,615,622     | 2,483,624       | 6,099,245       | 5,361,681     | 3,897,853       | 10,259,535      | 78,901,914    | 55,354,055      | 134,256,078    |
| 2009 | ≥60       | 1,930,328     | 1,296,997       | 3,227,326       | 810,936       | 553,286         | 1,364,222       | 1,238,603     | 304,030         | 1,542,633       | 8,827,847     | 5,735,294       | 14,563,141     |
|      | <60       | 8,827,847     | 5,735,294       | 14,563,141      | 3,816,134     | 2,524,816       | 6,340,951       | 5,480,623     | 3,466,208       | 8,946,831       | 64,671,541    | 39,195,223      | 103,866,764    |
| 2010 | ≥60       | 1,852,363     | 1,182,459       | 3,034,822       | 851,231       | 555,158         | 1,406,389       | 1,025,772     | 636,823         | 1,662,595       | 8,420,369     | 5,464,164       | 13,884,533     |
|      | <60       | 8,420,369     | 5,464,164       | 13,884,533      | 3,736,408     | 2,541,385       | 6,277,793       | 4,676,751     | 2,923,219       | 7,599,970       | 39,195,223    | 39,195,223      | 78,390,446     |
| 2011 | ≥60       | 3,977,573     | 4,442,934       | 8,420,547       | 1,324,583     | 2,057,240       | 3,381,823       | 1,524,159     | 2,387,994       | 3,912,153       | 12,804,070    | 5,125,377       | 17,929,447     |
|      | <60       | 12,804,070    | 5,125,377       | 17,929,447      | 4,392,512     | 2,504,467       | 6,996,979       | 5,058,449     | 2,636,394       | 7,694,843       | 64,671,541    | 39,195,223      | 103,866,764    |
| Total| ≥60       | 14,755,658    | 11,926,176      | 26,681,836      | 5,766,524     | 5,164,318       | 10,930,841      | 9,598,882     | 7,122,135       | 16,721,016      | 64,671,541    | 39,195,223      | 103,866,764    |
The RR for the PYLL rate in the rural districts was 1.54. The PYLL rates for the elderly were significantly different between rural and urban districts \( (W = 34.00, \ p = 0.018) \) (Figure 4). The RRs for the PYLL rates between the elderly and young showed increasing trends from 2005 to 2011 for both sex (Figure 5A) and district (Figure 5B).

**Figure 4.** Potential years of life lost rate for the elderly (≥60 years) and young (<60 years) populations in China, 2005–2011.

**Figure 5.** The change of RRs of PYLL rate by (A) sex and (B) district in China, 2005–2011.

3.4. Disability-Adjusted Life Years in the Elderly Population

Due to the smaller population base of the elderly, the DALYs of the elderly (75,013,661 healthy life years) were less than those of the young (94,664,862 healthy life years). The DALY rate of the elderly was 58.79/1000, which was 5.00 times that of the young (11.76/1000). The DALYs of the elderly in urban districts were 33,780,542 healthy life years, and the DALY rate was 56.20/1000, which was 5.40 times that of the young (10.42/1000) (Figure 6). The RR of the DALY rate in the rural districts was 4.63. The DALY rates of the elderly were significantly different between men and women \( p < 0.001 \) and between rural and urban districts \( p < 0.05 \) (Figure 6). The RRs for the PYLL rates tended to increase for sex (Figure 7A) and district (Figure 7B).
4. Discussion

Based on the published Chinese Cancer Registry Annual Report or related literature and the China Population and Employment Statistics Yearbooks, we estimated the cancer burden of elderly Chinese people by calculating indices such as the PYLL, DALY, and RR. The present study showed that the cancer incidence and related mortality in the elderly were significantly higher than those in the young; the mortality rates in the elderly exceeded that of the young by more than 12 times, and the RRs of the PYLL and DALY rates were significant, exceeding ratios of 2. In addition, we also find that cancer incidence and mortality in elderly Chinese is changing; the cancer burden in rural districts was higher than that in urban districts, and male elderly always had a higher cancer burden than female elderly. The findings also indicate that tumors have become a disease that is significantly influencing elderly people’s health in China.

With the increasing aging population, the incidence of cancer has also significantly increased. The cancer incidence and cancer-related mortality in the elderly Chinese population in the present study were higher than the global averages published on the GLOBOCAN website [22] and lower than those reported for developed countries such as Japan and the US, while cancer-related mortality was similar to
that in Korea. It is possible that the registry failed to report all of the cancer cases in the system due to medical conditions that were in the early stages [25]. Compared with the young, the cancer incidence and related mortality in the elderly increased sharply and were significantly higher than the global rates (133.8/100,000) in 2013. Organ hypofunction in the elderly could increase the susceptibility to or risk of cancer [26], and DNA damage has been reported as a main reason for cancer onset [27]. The anti-virus (human papillomavirus, hepatitis B virus, Epstein-Barr virus) ability of the immune system and the capacity for DNA repair decrease significantly with age, which could also contribute to the increased occurrence of and death from cancers in the elderly [28].

Cancer not only damages health but also shortens life expectancy. The PYLL and DALY rates for the elderly in the present study were more than two times those of the young, which was probably related with the large number of deaths in the elderly. Other studies have reported similar results, with >80% of cancer deaths occurring in the elderly [29]. Cancer-related mortality in the elderly in the present study was 13.53 times that of the young. The first potential reason is that the elderly have a higher probability of having the risk factors for cancer. Second, the anti-inflammatory ability of the elderly decreases sharply, and malnutrition can complicate cancers. These potential reasons for the high cancer-related mortality [30] in the elderly also explain the increased disease burden in the elderly.

DALYs are a key measure of the burden of cancer mortality based on the degree of illness and disability in patients and long-term survivors [31]. The cancer burden of elderly Chinese was determined using the two components of DALYs—YLL because of premature mortality and YLD. Based on a comparison with data for the global burden of cancer from 2008 [32], the DALY rate in the elderly was significantly higher than those in East Asia (21.97/1000) and globally (23.69/1000). The DALY rates of both sexes in the Chinese elderly were higher than those in East Asia (men 25.53/1000, women 18.53/1000) and globally (men 24.35/1000, women 23.01/1000). These results indicate that the cancer burden in elderly Chinese is substantial and related to the rapidly aging Chinese population and imperfect health care system in rural districts. However, age is one of the most important factors causing cancers, and improved access to high-quality treatment has not greatly improved survival for cancers associated with poor prognosis and subsequently high total DALY. Therefore, to alleviate the cancer burden, the health care system has to be improved to meet with the increasing need of treating cancers.

Differences in disease burden were found between the sexes and districts. Because men are more likely to have a number of unhealthy habits such as smoking, alcohol abuse, and high amounts of stress than women, they had a greater disease burden. The differences between districts can be explained by the imbalanced medical resources and income gap between the rural and urban districts.

In the present study, the ranking of cancer incidence and mortality in China was different from the most recent GLOBOCAN data from 2012 [1]. During the study period, China was focused on economic development, was involved in over-exploitation of natural resources, had high-polluting industries, and had a weak health care system, which might explain the differences in the rankings. Lung cancer remains the top ranked cancer in China, which might be due to environmental pollution, smoking, and the proportion of men in the population. Comparatively, breast cancer is the highest ranked cancer globally [1]. In China, the rates of breast cancer increased sharply from 2005 to the second position in 2011; the implementation of early diagnosis, screening examinations, and increasing awareness of self-examination might explain this increase. In addition, the incidences of lung, liver, stomach, and colorectal cancer remain high in the elderly, based on data from 2005 to 2009. Because of the lack of
recent annual cancer reports, these trends need to be analyzed further using continuous data to enable the consideration of early diagnosis, screening examinations, and interventions for healthy behaviors by the government or health care system. This is particularly important for relieving the cancer burden because of the aging population.

China has experienced a particularly sharp increase in the aging of the population, reaching the levels of developed countries in only half the time [33]. The elderly Chinese population has increased approximately 0.17% annually over the past 20 years, affecting all of the provinces [30]. This creates a serious challenge for the government because of the limited medical services and health resources. The results of the present study, which focused on population health issues, can provide guidance for development of health policies by the Chinese government.

5. Conclusions

In conclusion, this population-based study demonstrated that elderly Chinese have a considerable cancer burden, and this was higher in men and rural districts than in women and urban districts, respectively. Comprehensive measures for cancer prevention and treatment should be implemented to reduce this cancer burden. Future studies should be conducted with long-term, continuous data to evaluate the economic impact and factors influencing the cancer burden in the elderly.

Acknowledgments

Data collection was supported by the Major Public Health Fund of Xinjiang Production and Construction Crops (XPCC), No. 2100409 and the Corps Doctor Foundation, No. 2014BB018. We thank the health staff of the cancer prevention and control leading group of XPCC. The study is published with the permission of the Director General of the Medical School of Shihezi University, for whose support we are grateful. The Major Public Health Fund of Xinjiang Production and Construction Crops (XPCC), No. 2100409 and Natural Science Foundation of China (No. 81560053) supported this work.

Author Contributions

Shugang Li, Xuefei Zhang, Lijuan Pang and Feng Li designed the study with contributions from all authors and wrote the first draft. Shugang Li, Yizhong Yan, and Kui Wang coordinated the data collection. Dongsheng Rui, Xuefei Zhang, and Lijuan Pang analyzed the data with support from Shugang Li, and Feng Li. All authors contributed to the critical interpretation and writing of the paper and saw and approved the final version.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. WHO. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available online: http://globocan.iarc.fr (accessed on 17 May 2015).
2. Ferlay, J.; Shin, H.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide; IARC Cancer Base No. 10; International Agency for Research on Cancer: Lyon, France, 2010; Volume 2010, p. 29.

3. Liu, L. The global significance of China’s cancer burden and control effort. Ann. Transl. Med. 2014, 2, doi:10.3978/j.issn.2305-5839.2014.07.04.

4. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69–90.

5. Murray, C.J.; Ezzati, M.; Flaxman, A.D.; Lim, S.; Lozano, R.; Michaud, C.; Naghavi M, Salomon, J.A.; Shibuya, K.; Vos, T.; Wikler, D.; Lopez, A.D. GBD 2010: Design, definitions, and metrics. Lancet 2012, 380, 2063–2066.

6. National Bureau of Statistics of China. China Population and Employment Statistics Yearbook, 2011; China Statistics Press: Beijing, China, 2012.

7. Chen, W.; Zheng, R.; Zeng, H.; Zhang, S. Trend analysis of the changes of male/female, urban/rural incidences and average age of cancer patients in China 1989–2008. Chin. J. Oncol. 2014, 36, 796–800.

8. Leng, S.X.; Tian, X.P.; Durso, S.; Lazarus, G.; Lu, C.; Park, E.; Xie, H.; Kang, L.; Li, D.; Shen, T.; Fried, L.P. The aging population and development of geriatrics in China. J. Am. Geriatr. Soc. 2008, 56, 571–573.

9. Chen, W.; Zheng, R.; Zhang, S.; Zhao, P.; Zeng, H.; Zou, X. Annual report on status of cancer in China, 2012. Chin. J. Cancer Res. 2014, 26, 48–58.

10. Chen, W.; Zheng, R.; Zeng, H.; Zhang, S.; He, J. Annual report on status of cancer in China, 2011. Chi. J. Cancer Res. 2015, 27, 2–12.

11. Chen, W.Q.; Zheng, R.S.; Zhang, S.W.; Zhao, P.; Zeng, H.M.; Zou, X.N.; He, J. Annual report on status of cancer in China, 2010. Chin. J. Cancer Res. 2014, 26, 48–58.

12. Chen, W.; Zheng, R.; Zhang, S.; Zhao, P.; Zeng, H.; Zou, X. Annual report on status of cancer in China, 2009. Chin. J. Cancer Res. 2011, 23, 43–53.

13. Chen, W.; Zheng, R.; Zhang, S.; Zhao, P.; Zeng, H.; Zou, X. Annual report on status of cancer in China, 2008. Chin. J. Cancer Res. 2010, 22, 42–52.

14. Chen, W.; Zheng, R.; Zhang, S.; Zhao, P.; Li, G.; Wu, L. Report of cancer incidence and mortality in China, 2011. Chin. J. Cancer Res. 2014, 24, 1–10.
21. Morrow, R.H.; Hyder, A.A.; Murray, C.J.; Lopez, A.D. Measuring the burden of disease. *Lancet* **1998**, *352*, 1859–1861.

22. WHO. WHO Methods and Data Sources for Global Burden of Disease Estimates 2000–2011. Available online: http://www.who.int/healthinfo/statistics/GlobalDALYmethods_2000_2011.pdf?ua=1 (accessed on 10 May 2015).

23. WHO. Global Burden of Disease 2004 Update: Disability Weights for Diseases and Conditions. Available online: http://www.who.int/healthinfo/global_burden_disease/GBD2004_DisabilityWeights.pdf (accessed on 10 May 2015).

24. World Health Organization. Available online: www.who.int/healthinfo/global_burden_disease/tools_software/en/Weights.pdf (accessed on 10 May 2015).

25. Chen, H.; Wang, H.; Crimmins, E.M.; Chen, G.; Huang, C.; Zheng, X. The contributions of diseases to disability burden among the elderly population in China. *J. Aging Health* **2014**, *26*, 261–282.

26. Wong, G.; Lim, W.H.; Lewis, J.; Craig, J.C.; Turner, R.; Zhu, K.; Lim, E.M.; Prince, R. Vitamin D and cancer mortality in elderly women. *BMC Cancer* **2015**, *15*, doi:10.1186/s12885-015-1112-5.

27. Kidane, D.; Chae, W.J.; Czochor, J.; Eckert, K.A.; Glazer, P.M.; Bothwell, A.L.; Sweasy, J.B. Interplay between DNA repair and inflammation, and the link to cancer. *Crit. Rev. Biochem. Mol. Biol.* **2014**, *49*, 116–139.

28. Wolfgang, C.L.; Herman, J.M.; Laheru, D.A.; Klein, A.P.; Erdek, M.A.; Fishman, E.K.; Hruban, R.H. Recent progress in pancreatic cancer. *CA Cancer J. Clin.* **2013**, *63*, 318–348.

29. Zeeneldin, A.A.; Ramadan, H.; El Gammal, M.M.; Saber, M.M.; Elgamal, D.; Sherisher, M.A. Gastric carcinoma at Tanta Cancer Center: A comparative retrospective clinico-pathological study of the elderly versus the non-elderly. *J. Egypt. Natl. Cancer Inst.* **2014**, *26*, 127–137.

30. Johnson, C.M.; Wei, C.; Ensror, J.E.; Smolenski, D.J.; Amos, C.I.; Levin, B.; Berry, D.A. Meta-analyses of colorectal cancer risk factors. *Cancer Cause. Control* **2013**, *24*, 1207–1222.

31. Murray, C.J.; Lopez, A.D. The utility of DALYs for public health policy and research: A reply. *Bull. World Health Organ.* **1997**, *75*, 377–381.

32. Soerjomataram, I.; Lortet-Tieulent, J.; Parkin, D.M.; Ferlay, J.; Mathers, C.; Forman, D.; Bray, F. Global burden of cancer in 2008: A systematic analysis of disability-adjusted life-years in 12 world regions. *Lancet* **2012**, *380*, 1840–1850.

33. Long, M. The restriction of population aging on the population development strategy of China and the solution. *Popul. Dev.* **2013**, *19*, 52–63.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).